OKULO LTD


2021-04-012022-03-312022-03-31false11251527OKULO LTD2022-07-06iso4217:GBPxbrli:pure112515272021-04-01112515272022-03-31112515272021-04-012022-03-31112515272020-04-01112515272021-03-31112515272020-04-012021-03-3111251527bus:SmallEntities2021-04-012022-03-3111251527bus:AuditExempt-NoAccountantsReport2021-04-012022-03-3111251527bus:FullAccounts2021-04-012022-03-3111251527bus:PrivateLimitedCompanyLtd2021-04-012022-03-3111251527core:WithinOneYear2022-03-3111251527core:AfterOneYear2022-03-3111251527core:WithinOneYear2021-03-3111251527core:AfterOneYear2021-03-3111251527core:ShareCapital2022-03-3111251527core:SharePremium2022-03-3111251527core:RevaluationReserve2022-03-3111251527core:OtherReservesSubtotal2022-03-3111251527core:RetainedEarningsAccumulatedLosses2022-03-3111251527core:ShareCapital2021-03-3111251527core:SharePremium2021-03-3111251527core:RevaluationReserve2021-03-3111251527core:OtherReservesSubtotal2021-03-3111251527core:RetainedEarningsAccumulatedLosses2021-03-3111251527core:LandBuildings2022-03-3111251527core:PlantMachinery2022-03-3111251527core:Vehicles2022-03-3111251527core:FurnitureFittings2022-03-3111251527core:OfficeEquipment2022-03-3111251527core:NetGoodwill2022-03-3111251527core:IntangibleAssetsOtherThanGoodwill2022-03-3111251527core:ListedExchangeTraded2022-03-3111251527core:UnlistedNon-exchangeTraded2022-03-3111251527core:LandBuildings2021-03-3111251527core:PlantMachinery2021-03-3111251527core:Vehicles2021-03-3111251527core:FurnitureFittings2021-03-3111251527core:OfficeEquipment2021-03-3111251527core:NetGoodwill2021-03-3111251527core:IntangibleAssetsOtherThanGoodwill2021-03-3111251527core:ListedExchangeTraded2021-03-3111251527core:UnlistedNon-exchangeTraded2021-03-3111251527core:LandBuildings2021-04-012022-03-3111251527core:PlantMachinery2021-04-012022-03-3111251527core:Vehicles2021-04-012022-03-3111251527core:FurnitureFittings2021-04-012022-03-3111251527core:OfficeEquipment2021-04-012022-03-3111251527core:NetGoodwill2021-04-012022-03-3111251527core:IntangibleAssetsOtherThanGoodwill2021-04-012022-03-3111251527core:ListedExchangeTraded2021-04-012022-03-3111251527core:UnlistedNon-exchangeTraded2021-04-012022-03-3111251527core:MoreThanFiveYears2021-04-012022-03-3111251527core:Non-currentFinancialInstruments2022-03-3111251527core:Non-currentFinancialInstruments2021-03-3111251527dpl:CostSales2021-04-012022-03-3111251527dpl:DistributionCosts2021-04-012022-03-3111251527dpl:AdministrativeExpenses2021-04-012022-03-3111251527core:LandBuildings2021-04-012022-03-3111251527core:PlantMachinery2021-04-012022-03-3111251527core:Vehicles2021-04-012022-03-3111251527core:FurnitureFittings2021-04-012022-03-3111251527core:OfficeEquipment2021-04-012022-03-3111251527core:NetGoodwill2021-04-012022-03-3111251527core:IntangibleAssetsOtherThanGoodwill2021-04-012022-03-3111251527dpl:GroupUndertakings2021-04-012022-03-3111251527dpl:ParticipatingInterests2021-04-012022-03-3111251527dpl:GroupUndertakingscore:ListedExchangeTraded2021-04-012022-03-3111251527core:ListedExchangeTraded2021-04-012022-03-3111251527dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-04-012022-03-3111251527core:UnlistedNon-exchangeTraded2021-04-012022-03-3111251527dpl:CostSales2020-04-012021-03-3111251527dpl:DistributionCosts2020-04-012021-03-3111251527dpl:AdministrativeExpenses2020-04-012021-03-3111251527core:LandBuildings2020-04-012021-03-3111251527core:PlantMachinery2020-04-012021-03-3111251527core:Vehicles2020-04-012021-03-3111251527core:FurnitureFittings2020-04-012021-03-3111251527core:OfficeEquipment2020-04-012021-03-3111251527core:NetGoodwill2020-04-012021-03-3111251527core:IntangibleAssetsOtherThanGoodwill2020-04-012021-03-3111251527dpl:GroupUndertakings2020-04-012021-03-3111251527dpl:ParticipatingInterests2020-04-012021-03-3111251527dpl:GroupUndertakingscore:ListedExchangeTraded2020-04-012021-03-3111251527core:ListedExchangeTraded2020-04-012021-03-3111251527dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2020-04-012021-03-3111251527core:UnlistedNon-exchangeTraded2020-04-012021-03-3111251527core:NetGoodwill2022-03-3111251527core:IntangibleAssetsOtherThanGoodwill2022-03-3111251527core:LandBuildings2022-03-3111251527core:PlantMachinery2022-03-3111251527core:Vehicles2022-03-3111251527core:FurnitureFittings2022-03-3111251527core:OfficeEquipment2022-03-3111251527core:AfterOneYear2022-03-3111251527core:WithinOneYear2022-03-3111251527core:ListedExchangeTraded2022-03-3111251527core:UnlistedNon-exchangeTraded2022-03-3111251527core:ShareCapital2022-03-3111251527core:SharePremium2022-03-3111251527core:RevaluationReserve2022-03-3111251527core:OtherReservesSubtotal2022-03-3111251527core:RetainedEarningsAccumulatedLosses2022-03-3111251527core:NetGoodwill2021-03-3111251527core:IntangibleAssetsOtherThanGoodwill2021-03-3111251527core:LandBuildings2021-03-3111251527core:PlantMachinery2021-03-3111251527core:Vehicles2021-03-3111251527core:FurnitureFittings2021-03-3111251527core:OfficeEquipment2021-03-3111251527core:AfterOneYear2021-03-3111251527core:WithinOneYear2021-03-3111251527core:ListedExchangeTraded2021-03-3111251527core:UnlistedNon-exchangeTraded2021-03-3111251527core:ShareCapital2021-03-3111251527core:SharePremium2021-03-3111251527core:RevaluationReserve2021-03-3111251527core:OtherReservesSubtotal2021-03-3111251527core:RetainedEarningsAccumulatedLosses2021-03-3111251527core:NetGoodwill2020-04-0111251527core:IntangibleAssetsOtherThanGoodwill2020-04-0111251527core:LandBuildings2020-04-0111251527core:PlantMachinery2020-04-0111251527core:Vehicles2020-04-0111251527core:FurnitureFittings2020-04-0111251527core:OfficeEquipment2020-04-0111251527core:AfterOneYear2020-04-0111251527core:WithinOneYear2020-04-0111251527core:ListedExchangeTraded2020-04-0111251527core:UnlistedNon-exchangeTraded2020-04-0111251527core:ShareCapital2020-04-0111251527core:SharePremium2020-04-0111251527core:RevaluationReserve2020-04-0111251527core:OtherReservesSubtotal2020-04-0111251527core:RetainedEarningsAccumulatedLosses2020-04-0111251527core:AfterOneYear2021-04-012022-03-3111251527core:WithinOneYear2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:CostValuation2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-04-012022-03-3111251527core:Non-currentFinancialInstrumentscore:CostValuation2022-03-3111251527core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-3111251527core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-3111251527core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-3111251527core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-3111251527core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-3111251527core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-3111251527core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-3111251527core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-3111251527core:Non-currentFinancialInstrumentscore:CostValuation2021-03-3111251527core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2021-03-3111251527core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2021-03-3111251527core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2021-03-3111251527core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2021-03-3111251527core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2021-03-3111251527core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2021-03-3111251527core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2021-03-3111251527core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2021-03-3111251527bus:Director12021-04-012022-03-3111251527bus:Director22021-04-012022-03-311125152712021-04-012022-03-31

OKULO LTD

Registered Number
11251527
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2022

OKULO LTD
Company Information
for the year from 1 April 2021 to 31 March 2022

Directors

S Campbell
D Harris

Registered Address

6a Cornwallis Crescent
6a Cornwallis Crescent
Bristol
BS8 4PL

Registered Number

11251527 (England and Wales)
OKULO LTD
Statement of Financial Position
31 March 2022

Notes

2022

2021

£

£

£

£

Fixed assets
Intangible assets810,9386,745
Tangible assets99,2089,003
20,14615,748
Current assets
Debtors11192,30956,534
Cash at bank and on hand177,792537,569
370,101594,103
Creditors amounts falling due within one year12(113,151)(43,293)
Net current assets (liabilities)256,950550,810
Total assets less current liabilities277,096566,558
Creditors amounts falling due after one year13(33,964)(36,750)
Net assets243,132529,808
Capital and reserves
Called up share capital176169
Share premium1,426,4331,071,078
Other reserves276,232102,968
Profit and loss account(1,459,709)(644,407)
Shareholders' funds243,132529,808
  • The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
  • The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
  • The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
  • These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The directors have chosen to not file a copy of the company’s profit and loss account.
The financial statements were approved and authorised for issue by the Board of Directors on 6 July 2022, and are signed on its behalf by:
S Campbell
Director
Registered Company No. 11251527
OKULO LTD
Notes to the Financial Statements
for the year ended 31 March 2022

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Principal activities
The principal activity of the company throughout the year under review was the development of medical testing technology.
4.Basis of measurement used in financial statements
The financial statements have been prepared under the historical cost convention.
5.Accounting policies
Functional and presentation currency policy
The financial statements are presented in sterling and this is the functional currency of the company.
Property, plant and equipment policy
Tangible assets are stated at cost (or deemed cost), less accumulated depreciation and accumulated impairment losses. Cost includes the original purchase price, costs directly attributable to bringing the asset to its working condition for its intended use, dismantling and restoration costs. Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Straight line (years)
Office Equipment3
Intangible assets policy
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. Included in intangible assets are Patents and Trademarks which are being amortised evenly over their estimated useful life of ten years.
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Taxation policy
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Tax credits shown on the income statement represent payable tax credits receivable from HMRC as a result of claims made under HMRC's R&D tax relief schemes.
Research and development policy
Revenue expenditure on research and development is written off in the period in which it is incurred. The company qualifies to make claims under both the SME R&D tax relief scheme and the Research and Development Expenditure Credit scheme. Benefits arising from successful claims under the SME R&D tax relief scheme are reflected 'below the line' as a reduction in the Corporation Tax charge or, if loss making, as a Corporation Tax credit. Benefits arising from successful claims under the RDEC scheme are subject to Corporation Tax. Gross benefits are therefore reflected ‘above the line’ in Other income with the corresponding charge to Corporation Tax reflected in the Corporation Tax charge, or credit (if loss making). Benefits receivable from R&D claims are recognised in the reporting period in which the qualifying expenditure is incurred.
Foreign currency translation and operations policy
Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions. At each reporting period end foreign currency monetary items are translated using the closing rate. Non monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined. Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at the period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the profit and loss account.
Government grants and other government assistance policy
Other operating income includes grant income received. A grant that does not impose specified future performance related conditions is recognised in other income when the grant proceeds are received or receivable. In the case of performance-related grants, income is recognised only when the performance-related conditions are satisfied.
Leases policy
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate. Share Based Payments The company operates an equity-settled compensation plan. The fair value of the services received in exchange for the grant of the options is recognised as an expense in the income statement. The total amount to be expensed over the vesting period is determined by reference to the fair value of the options granted, excluding the impact of any non-market vesting conditions (for example, profitability and sales growth targets). Non-market vesting conditions are included in assumptions about the number of options that are expected to vest. At each statement of position date, the entity revises its estimates of the number of options that are expected to vest. It recognises the impact of the revision to original estimates, if any, in the income statement. The credit entry is taken to reserves because the share options are equity-settled.
Valuation of financial instruments policy
The Company has chosen to adopt Sections 11 and 12 of FRS 102 in respect of financial instruments. The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non puttable ordinary shares. Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out right short term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost. Financial assets and liabilities are offset and the net amount reported in the Statement of Financial Position when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Cash and cash equivalents Cash and cash equivalents comprise cash on hand and demand deposits and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk to changes in value.
Going concern
The financial statements have been prepared on a going concern basis. The company incurred losses during the year however the directors have a reasonable expectation that trading will improve once the research and development phase has been completed and the company is fully operational. The directors have been successful in attracting new investment during the year and are of the opinion that the company has sufficient resources to meet its future obligations, if and when, they become due. The directors are therefore of the opinion that they should continue to adopt the going concern basis of accounting in preparing the financial statements.
6.Critical estimates and judgements
Share based payments as set out in note 7 to the accounts below have been made to the employees of the company. As disclosed in the share based payments accounting policy note above, the fair value of the options granted is recognised in the income statement over the course of the vesting period. The fair value is estimated to be £2.64 per share which is based on the value of ordinary shares issued at or around the time of granting the options. No other significant judgements or estimates have been used in order to arrive at the figures contained within the financial statements.
7.Employee information
The company operates an EMI qualifying share option scheme. At the statement of financial position date the company had granted 366,321 share options to 8 employees. At the statement of financial position date 67,619 options had vested (2021: 9,580), 0 had been exercised (2021: 0) and 9,580 had lapsed (2021: 0). A portion of share options granted typically vest on the date of grant with remaining options vesting between 1 and 59 months from the grant date. The company also operates an unapproved share option scheme. At the statement of financial position date the company had granted 50,272 share options to 4 employees. At the statement of financial position date 44,482 options had vested (2021: 26,245), 0 had been exercised (2021: 0) and 0 had lapsed (2021: 0). A portion of share options granted typically vest on the date of grant with remaining options vesting between 1 and 24 months from the grant date.

20222021
Average number of employees during the year1611
8.Intangible assets

Other

Total

££
Cost or valuation
At 01 April 217,4367,436
Additions5,1065,106
At 31 March 2212,54212,542
Amortisation and impairment
At 01 April 21691691
Charge for year913913
At 31 March 221,6041,604
Net book value
At 31 March 2210,93810,938
At 31 March 216,7456,745
9.Property, plant and equipment

Office Equipment

Total

££
Cost or valuation
At 01 April 2113,34813,348
Additions5,5485,548
At 31 March 2218,89618,896
Depreciation and impairment
At 01 April 214,3454,345
Charge for year5,3435,343
At 31 March 229,6889,688
Net book value
At 31 March 229,2089,208
At 31 March 219,0039,003
10.Description of event after reporting date
Subsequent to the end of the reporting year the company issued 30,888 Ordinary shares of £0.0001 each for total consideration of £160,000.
11.Debtors

2022

2021

££
Amounts owed by group undertakings21,091-
Other debtors171,21856,534
Total192,30956,534
12.Creditors within one year

2022

2021

££
Trade creditors / trade payables48,44719,275
Bank borrowings and overdrafts8,7378,250
Taxation and social security13,99414,131
Other creditors41,9731,637
Total113,15143,293
13.Creditors after one year

2022

2021

££
Bank borrowings and overdrafts33,96436,750
Total33,96436,750
The company's bank borrowings and overdrafts, split across creditors due within one year and creditors due after one year, are guaranteed by the UK government under the Bounce Back Loan scheme.